Mexidol

Emoxypine succinate

Mexidol (Emoxypine succinate) is a cognitive & mood research compound. Succinate-based antioxidant and membrane stabilizer — reduces oxidative stress and improves cerebral metabolism and blood flow.

How Mexidol works

Succinate-based antioxidant and membrane stabilizer — reduces oxidative stress and improves cerebral metabolism and blood flow.

Proposed benefits

Researched for focus, memory, neuroprotection, mood and stress resilience.

Where to get Mexidol

The evidence for Mexidol

Graded by what exists behind each claim.

Human clinical evidence

• The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.

📊 Correlative data

• One of the most-prescribed drugs in Russia, used for cerebrovascular disease, anxiety and alcohol withdrawal, with a large domestic clinical literature. It is genuinely widely used medicine there and essentially unknown elsewhere.
• Reported experience outside Russia is of a mild anxiolytic and clear-headed effect, with a good tolerability record.

🧪 Theoretical / extrapolated

• Ethylmethylhydroxypyridine succinate — a succinate salt of an antioxidant pyridine. Proposed to act as a membrane-stabilizing antioxidant and to feed succinate directly into the Krebs cycle, supporting ATP production under hypoxic stress.
• The succinate arm is the mechanistically interesting part: bypassing complex I to supply complex II is a real strategy in ischemia research, and it predicts that the effect should be largest where oxygen delivery is the limiting factor.

How to read the Soviet clinical series →

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Mexidol actually does

It is a salt, and the arithmetic of that is the first thing nobody does. Ethylmethylhydroxypyridine succinate is 2-ethyl-6-methylpyridin-3-ol paired one-to-one with succinic acid: C12H17NO5, 255.27 Da, of which the base is 137.18 Da and the acid 118.09 Da. So succinic acid is 46% of every milligram. A 125 mg tablet is 67 mg of emoxypine plus 58 mg of succinic acid; a 250 mg tablet is 132 mg plus 116 mg, which is 0.98 mmol of succinate. Any comparison between this and a succinate supplement, or between two dose regimens, has to be made on that number rather than on the tablet strength.

Half one: the 3-hydroxypyridine. A phenolic hydroxyl on an electron-rich pyridine ring is a hydrogen-atom donor — it terminates lipid-peroxidation chain reactions in membranes the way alpha-tocopherol does, by giving up the OH hydrogen to a lipid peroxyl radical and leaving behind a resonance-stabilized radical that does not propagate. That is a physical chemistry mechanism, not a receptor mechanism, and it predicts that the readout is a peroxidation product rather than any binding assay. Note also what the ring is: 2-ethyl-6-methylpyridin-3-ol is a substituted 3-hydroxypyridine, the same core as pyridoxine. Nothing published tests whether it interacts with the enzymes that handle vitamin B6 — pyridoxal kinase and pyridoxine 5'-phosphate oxidase — and that is an extrapolation from the scaffold, flagged as such, rather than a finding.

Half two: the succinate, and here is the problem the marketing has never met. The selling story is that succinate feeds complex II directly and bypasses complex I when oxygen is short. The counter-story is the best-cited paper in the field: Chouchani 2014 showed that ischemic accumulation of succinate is a universal metabolic signature of tissue damage, and that it is precisely the rapid re-oxidation of that accumulated succinate at reperfusion which drives reverse electron transport at complex I and the superoxide burst that causes reperfusion injury — with pharmacological suppression of that step reducing injury in heart-attack and stroke models Chouchani 2014. So a drug that is 46% succinic acid, given in and around ischemia, is delivering the exact metabolite whose accumulation the landmark paper identifies as the injury signal. Three readings survive: the antioxidant half neutralizes what the succinate half creates; the dose is too small against endogenous flux to matter; or timing saves it, because a tablet given days after an event is not the same as succinate piled up during occlusion. Nobody has run the experiment that separates those three. This tension is not in any Mexidol review, in either language.

Transporters, where the real interaction lives. EMHPS is an inhibitor but not a substrate of both ABCB1 (P-glycoprotein) and SLCO1B1 (OATP1B1); the authors judged systemic effects clinically insignificant but stated that ABCB1 inhibition in the gastrointestinal tract should be tested Shchulkin 2023. Separately, in HepG2 cells EMHPS at 500 µM raised OATP1B1 content, and from 10 µM upwards it reduced the uptake of atorvastatin, an OATP substrate Erokhina 2023. Not being a substrate is why absorption is not efflux-limited; being an inhibitor is why what you take with it matters.

Cell, rodent, human — and where it stops

In cells. HepG2 monolayers, EMHPS at 1–500 µM, transporter content by protein assay and function by atorvastatin accumulation Erokhina 2023; ABCB1 and SLCO1B1 systems, inhibition without substrate behavior Shchulkin 2023. Both are transporter pharmacology. Neither is an antioxidant or an antihypoxic experiment, which is a fair summary of the modern in-vitro literature on this drug: the mechanistic work being done today is about drug interactions, not about the mechanism it is sold for.

In humans, and the volume is real. The MEMO trial randomized 318 patients aged 40–90 across 15 centers in Russia and Uzbekistan, double-blind and placebo-controlled: 500 mg intravenously daily for 14 days, then 250 mg orally three times a day for 60 days. The Montreal Cognitive Assessment favored active treatment with p<0.000001 and a 95% confidence interval whose lower bound was 1.51 points, with secondary gains on digit symbol substitution, fatigue, anxiety, balance and quality of life, and comparable safety Fedin 2021. A 2024 meta-analysis pooled 10 prospective randomized trials, 482 patients on Mexidol against 455 controls, and reported a MoCA effect size of 2.06 points (95% CI 0.98–3.14, p=0.0002) Zakharov 2024.

The obstacles, and the first is arithmetic rather than opinion. (1) Every positive trial starts with two weeks of intravenous loading. MEMO gave 500 mg/day IV for 14 days — 7,000 mg parenterally — before a single tablet, then 750 mg/day orally. This site's protocol is 125–250 mg, one to three times a day, orally, with no loading phase. At the bottom of that range a person is taking one sixth of the trial's oral dose and none of its intravenous dose, which means they are not running the regimen any of the evidence describes. (2) The 2.06-point MoCA difference sits close to the test's own noise. MoCA is a 30-point instrument with a documented practice effect on repeat administration; a two-point group difference is a real signal in a blinded trial and is not a clinically dramatic one, and the meta-analysis's own confidence interval reaches down to 0.98 Zakharov 2024. (3) The entire literature comes from one clinical research system. Ten trials, one country's journal family, overlapping investigator groups between the component studies and the meta-analysis that pools them. No trial outside that system has replicated it, and that is a statement about the evidence base rather than about the drug. (4) The indication does not exist elsewhere. ‘Chronic brain ischemia’ is a routine diagnosis in Russian neurology and essentially absent from Western classification, so there is no matched population in which to attempt a replication even in principle.

Mexidol pharmacokinetics — how much of it actually gets in

The catalog says ~2–3 hours. Here is what has to be true behind that, and what the salt does to the number.

Two molecules leave on two different schedules. The emoxypine half carries a phenolic hydroxyl, which is the classic substrate for phase II conjugation — glucuronidation and sulfation — followed by renal excretion of the conjugate; a 2–3 hour half-life is exactly what that predicts and is why the trials dose it three times a day Fedin 2021. The succinate half has no half-life worth quoting at all, because it enters the citric acid cycle and is oxidized by succinate dehydrogenase within minutes, becoming indistinguishable from the succinate the mitochondrion was already making. One tablet, two disposal routes, and only one of them is a pharmacokinetic question.

The succinate load, in numbers. 250 mg of salt is 116 mg of succinic acid, 0.98 mmol. Three times a day is 2.94 mmol. The 500 mg intravenous dose used in MEMO is 1.96 mmol pushed into the circulation over minutes. Resting plasma succinate in healthy people sits in the low micromolar range; even if only a tenth of an intravenous dose stayed extracellular for a few minutes, the transient would be many multiples of baseline. Whether that actually happens is unmeasured — no published study reports plasma succinate after a Mexidol dose in a human — and given Chouchani's finding Chouchani 2014, it is the number this drug most needs and least has.

The oral barrier, and why it is unusually favorable. EMHPS is not a substrate of ABCB1 Shchulkin 2023, so intestinal P-glycoprotein does not pump it back into the lumen, and it is not a substrate of SLCO1B1 either, so hepatic uptake is not carrier-limited. That is a mechanistic reason to expect good and fairly consistent oral absorption, and it is a rare case on this site where a transporter study explains why an oral route works rather than why it does not. The flip side is the interaction: inhibiting intestinal ABCB1 raises the absorbed fraction of everything else that is a P-glycoprotein substrate taken at the same time, which is the specific test the authors say has not been done Shchulkin 2023.

Route. The evidence is a sequential intravenous-then-oral course; the market outside Russia is tablets only. The injectable solution is 50 mg/mL and the trial dose was 500 mg daily, which is 10 mL — a volume worth noticing for anyone who assumes an ampoule is interchangeable with a capsule.

What would have to be true, and how you would know it was not

Four predictions. Two of them argue against the way this compound is actually used.

1. Against: MoCA will not move in a healthy adult, and the trial population is the reason. MEMO enrolled 40- to 90-year-olds with a cerebrovascular diagnosis and moved the score by around two points Fedin 2021 Zakharov 2024. A cognitively intact 30-year-old ceilings the instrument at baseline. Retest at 8 weeks if you want, but understand in advance that a null result would not falsify anything — which is a reason to be skeptical of anybody reporting a cognitive gain from it.

2. Against, and this is the one with a real hazard: a P-glycoprotein substrate taken alongside should rise. EMHPS inhibits ABCB1 and its own investigators flagged the gut as the place to look Shchulkin 2023. If you take it with digoxin, or with a direct oral anticoagulant, the prediction is a higher exposure to that drug rather than to this one. Marker and window: a serum digoxin level within 7 days of adding it; for an anticoagulant, unexplained bruising or bleeding inside the first fortnight. This prediction is the reason the ‘stacks cleanly with the racetams’ framing should not be extended to prescription medicines.

3. Uric acid is the cheapest test of whether the succinate arm is real at these doses. Purine turnover and the citric acid cycle are coupled through adenine nucleotide handling; a genuine, sustained shift in mitochondrial substrate supply is the kind of thing that nudges urate. Prediction: at 750 mg/day of salt — 2.94 mmol of succinic acid, against a daily whole-body citric-acid-cycle flux measured in hundreds of millimoles — uric acid will not move at all, and a change means something other than the succinate is happening. Draw it at baseline and 12 weeks, fasted, away from alcohol and from a weight-loss phase.

4. High-sensitivity CRP and GGT are the honest pair for a compound sold as an antioxidant. If chain-breaking antioxidant activity is systemic at oral doses, the cheapest visible consequence is a small fall in hs-CRP in somebody whose baseline is elevated; GGT is on the list because it rises with oxidative stress and hepatic glutathione turnover and is the one liver enzyme that behaves like a redox marker. Retest both at 12 weeks. If neither moves while the person reports feeling better, the effect is somewhere a blood draw cannot see, and saying that plainly is more useful than pretending otherwise.

What nobody has tested yet

Five experiments. The first two would settle arguments that have run for twenty years.

1. Nobody has split the salt. Emoxypine base alone, succinic acid alone, and the 1:1 salt, at equal molar doses, against the same endpoint in the same animals. The drug has been in clinical use for decades and the experiment that says which half does the work — or whether the combination is more than the sum — has never been published. It is a three-arm rodent study with an off-the-shelf readout.

2. Nobody has measured plasma succinate after a dose in a human. Succinate is a routine target on any metabolomics platform. A time course after 250 mg orally and after 500 mg intravenously, in six people, would convert the entire ‘feeds the Krebs cycle’ claim from a diagram into a curve — and would say whether the exposure is large enough to engage the mechanism Chouchani described Chouchani 2014 at all.

3. Nobody has run the timing experiment the reperfusion literature demands. Same rodent stroke or myocardial infarction model, succinate-containing Mexidol given before reperfusion versus after, infarct volume as the endpoint. The mechanism predicts opposite signs for the two arms Chouchani 2014. Nobody has looked, and Mexidol is given clinically in exactly the window where the sign is in doubt.

4. Nobody has done the digoxin study its own authors asked for. Shchulkin's paper ends by saying intestinal ABCB1 inhibition should be tested Shchulkin 2023. The standard design is a digoxin AUC study in 12 healthy volunteers with and without the inhibitor. It has not been run, which means the one interaction with a plausible clinical consequence is the one nobody has quantified.

5. Nobody has replicated any of it outside the Russian-language system. Ten randomized trials and a meta-analysis Zakharov 2024 constitute more human evidence than most compounds in this catalog will ever have, and they all come from one place. A single independent 100-patient trial with a MoCA endpoint would do more for this drug's standing than the next ten domestic ones.

Mexidol — its own safety story, not its class's

The class block warns about stimulants and sleep. Neither applies. Four things do.

1. The interaction is a transporter interaction, not a receptor one. EMHPS inhibits ABCB1 and SLCO1B1 without being a substrate of either Shchulkin 2023, and reduces atorvastatin uptake into hepatocytes from 10 µM upwards Erokhina 2023. Practically: statins, digoxin, direct oral anticoagulants and other P-glycoprotein substrates are the drugs to think about, and the direction of the error is more of the other drug rather than less. Both papers judged the systemic effect clinically insignificant by the FDA's Cmax/IC50 approach; both also identify the gut as the place that assessment does not cover.

2. Anyone drug-tested should know this class is under discussion. A 2024 review in a doping-control journal examined Mexidol and the wider succinate-derivative family as antihypoxic and anti-ischemic metabolic modulators used as ergogenic aids in athletes, and concluded that some of them could be worth considering as prohibited substances in sport Jędrejko 2024. That is not a ban and it is a warning shot, and it is the single most decision-relevant fact on this page for a competing athlete.

3. The ampoule is a different product from the tablet. The trial evidence for parenteral use is 500 mg/day intravenously under supervision for 14 days Fedin 2021. Nothing about self-injecting an imported 50 mg/mL ampoule — sterility, technique, the 10 mL volume, the absence of anyone watching — is covered by that trial's safety data, and the safety data is the part people quote while changing the setting.

4. The B6 look-alike, flagged as extrapolation. The active ring is a 3-hydroxypyridine, structurally the same class as pyridoxine, and at 750 mg/day the molar quantity of substituted hydroxypyridine entering the body is orders of magnitude above any dietary B6 intake. Nothing published tests whether it competes at pyridoxal kinase, at pyridoxine 5'-phosphate oxidase, or at the transporters that move B6 vitamers. It probably does not matter. It is unmeasured, it is specific to this molecule rather than to its class, and the marker that would notice is a plasma pyridoxal-5'-phosphate before and after a course.

Sources read for this page

• Fedin AI, Zakharov VV, Tanashyan MM, Chukanova EI, Madzhidova EN, Shchepankevich LA, Ostroumova OD. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova 2021;121(11):7-16 · PMID 34932280
• Zakharov VV, Vakhnina NV. The use of Mexidol in patients with mild (moderate) cognitive impairment: results of a meta-analysis. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova 2024;124(1):82 · PMID 38261288
• Shchulkin AV, Erokhina PD, Goncharenko AV, Mylnikov PY, Chernykh IV, Abalenikhina YV, Kotliarova MS, Yakusheva EN. Ethylmethylhydroxypyridine Succinate Is an Inhibitor but Not a Substrate of ABCB1 and SLCO1B1. Pharmaceuticals (Basel) 2023;16(11):1529 · PMID 38004395
• Erokhina PD, Abalenikhina YV, Mylnikov PY, Petrov AV, Ganina SO, Konyakhin EA, Shchulkin AV, Yakusheva EN. The Effect of Original Russian Neurotropic Drugs on Organic Anion Transporting Polypeptides OATP1B1 and OATP1B3. Bulletin of Experimental Biology and Medicine 2023;176(2):170 · PMID 38198100
• Chouchani ET, Pell VR, Gaude E, Aksentijević D, Sundier SY, Robb EL, Logan A, Nadtochiy SM, Ord ENJ, Smith AC, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 2014;515(7527):431-435 · PMID 25383517
• Jędrejko K, Catlin O, Stewart T, Muszyńska B. Mexidol, Cytoflavin, and succinic acid derivatives as antihypoxic, anti-ischemic metabolic modulators, and ergogenic aids in athletes and consideration of their potential as performance enhancing drugs. Drug Testing and Analysis 2024 · PMID 38403950

Mexidol — safety, predicted from mechanism

Mexidol — interference & stacking

Bloodwork to run alongside Mexidol

Baseline first, then again at 8–12 weeks.

The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.

Check results you already have → · All 103 markers A–Z

Mexidol — frequently asked questions

What Mexidol is used for

Mexidol appears under 1 goal in the goal router.

Related Cognitive & Mood compounds

← Explore the full Protocol Vault

↑ Back to on this page